Johnson & Johnson is scheduled to report second-quarter earnings before the market open on Tuesday.
Most recent news about J&J JNJ, -0.14% has been about its legal problems, but some analysts still think the future is bright for the baby-powder maker, thanks to a highly diversified slate of products spanning consumer health, pharmaceuticals and medical devices.
“We see JNJ’s diversified portfolio… as a potential strength,” analysts at Goldman Sachs wrote in a note to clients in May. That diversification means the company “will be less impacted by potential drug pricing headlines [and] policy proposals ahead of the 2020 presidential election, as was the case in 2015,” they wrote.
J&J is still facing thousands of lawsuits over the safety of its talc-containing baby powder and its alleged role in fueling the opioid crisis. Last year, a jury awarded $4.7 billion in damages to 22 women and their families who blamed their cases of ovarian cancer on asbestos in the company’s talc products, though J&J is appealing the verdicts. In May, the company was ordered to pay $325 million to a woman who claimed its talc powder contributed to her diagnosis of mesothelioma, a rare, asbestos-linked cancer. J&J is currently facing a legal battle with the state of Oklahoma, which sued the company over allegations that its marketing practices contributed to the opioid crisis. That litigation could potentially cost J&J up to $17.5 billion dollars — the cost of a 30-year abatement plan the state presented to fix the opioid problem.
Read: Health care is one of the stock market’s healthiest sectors right now
Also read: Judge knocks down Trump rule requiring drug ads to reveal prices
Shares of the company dropped in May when the Oklahoma trial kicked off, falling to $131 per share. At the time, Cowen analyst Joshua Jennings said it would be hard for prosecutors to make a strong case against J&J, calling the decline “overdone.” J&J’s stock has recovered since then and is now trading at around $141 a share. Despite the company’s many legal issues, it’s clear that Wall Street still believes in J&J.
Here’s what analysts are expecting on Tuesday from the health-products giant.
Stock reaction: Shares of J&J, a Dow component, have lagged behind the broader market DJIA, +0.29% SPX, +0.45% this past year. However, they have outperformed the S&P 500’s health-care ETF, rising 9.5% in the year to date compared with the Health Care Select Sector SPDR Fund’s XLV, +0.34% 7.7%.
On FactSet, J&J has an average rating of overweight. Eight analysts have a hold rating on the stock, while 10 have a buy or overweight rating and one has an underweight or sell rating.
The average price target for the stock is $149.35, according to FactSet. Company shares were valued at $141.37 Wednesday morning.
Earnings: Analysts expect J&J to report second-quarter earnings of $2.43 per share, a jump up from the $2.10 per share posted in the year-earlier period, according to FactSet. The software platform Estimize, which crowdsources estimates from buy-side and sell-side analysts, hedge funds, academics and others, also has the company earning $2.43.
Revenue: Analysts polled by FactSet expect the company to report revenue of $20.29 billion, down from $20.83 billion in the year-earlier period, dragged down by lower estimates in the company’s medical devices unit — $6.435 billion versus $6.972 billion a year ago.
Estimize has J&J reporting $20.468 billion in sales.